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There is considerable heterogeneity in individuals’ risk of disease and thus the absolute ben-
efits and harms of population-wide screening programmes. Using colorectal cancer (CRC)
screening as an exemplar, we explored how people make decisions about screening when
presented with information about absolute benefits and harms, and how those preferences
vary with baseline risk, between screening tests and between individuals.
Method
We conducted two linked studies with members of the public: a think-aloud study exploring
decision making in-depth and an online randomised experiment quantifying preferences. In
both, participants completed a web-based survey including information about three screen-
ing tests (colonoscopy, sigmoidoscopy, and faecal immunochemical testing) and then up to
nine scenarios comparing screening to no screening for three levels of baseline risk (1%,
3% and 5% over 15 years) and the three screening tests. Participants reported, after each
scenario, whether they would opt for screening (yes/no).
Results
Of the 20 participants in the think-aloud study 13 did not consider absolute benefits or harms
when making decisions concerning CRC screening. In the online experiment (n = 978), 60%
expressed intention to attend at 1% risk of CRC, 70% at 3% and 77% at 5%, with no differ-
ences between screening tests. At an individual level, 535 (54.7%) would attend at all three
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risk levels and 178 (18.2%) at none. The 27% whose intention varied by baseline risk were
more likely to be younger, without a family history of CRC, and without a prior history of
screening.
Conclusions
Most people in our population were not influenced by the range of absolute benefits and
harms associated with CRC screening presented. For an appreciable minority, however,
magnitude of benefit was important.
Introduction
Many countries have introduced population wide screening programmes for a number of can-
cers, including colorectal (CRC) [1], breast [2], and cervical [3] cancers. These reduce disease
specific mortality and, in the case of CRC and cervical cancer, disease specific incidence, at a
population level [4–7]. However, within the general population, individuals’ risk of developing
CRC varies considerably depending on factors such as age, sex, body mass index (BMI), life-
style and genetics [8]. The potential benefits of screening therefore vary substantially between
individuals. All screening programmes are also associated with harms. These include direct
harms to those screened as well as indirect harms through diversion of resources away from
other services. Direct harms to those screened include complications arising from the screen-
ing tests and/or subsequent investigations, the identification or treatment of conditions that
may never cause illness (overdiagnosis and overtreatment) and psychological consequences.
These harms also vary with age and the presence or absence of co-morbidities. There are,
therefore, potentially large differences between individuals in the potential absolute benefits
and harms of screening, and thus in the net benefit.
This individual level variation in the absolute benefits and harms of screening has led to
two proposals. The first is for a shift in screening recommendations from promoting uptake
by emphasising average population level benefits towards enabling an approach in which indi-
viduals receive support to make informed decisions based on personalised estimates of benefits
and harms [9, 10]. The second is risk-stratified screening, in which the age of first invitation,
the choice of test and/or the screening interval are tailored to an individual’s risk [11].
By design, supporting more individualised informed decision making requires individuals
to be informed of the absolute benefits and harms from screening. Introducing risk-stratified
screening, in particular using risk to determine the age at first invitation, would also likely
require communication of risk. Although providing information on risk may influence the
decision to take up screening at an individual level and support shared decision-making [12,
13], many in the general population do not easily understand the concept of risk or probability
[14, 15] and even individuals who appear to understand and recall risk information often do
not believe that the information reflects their own risk [16]. Understanding how individuals
use information about benefits and harms of screening and how the magnitude of the absolute
benefits and harms influences uptake is therefore important.
Existing research in this area has largely focused on stated choice studies (most commonly
discrete choice analyses [17–20]). These studies have shown that the type of screening test,
preparation required, screening interval, and risk reduction all influence screening prefer-
ences, with the risk reduction the most important attribute in one study [17]. There are, how-
ever, a number of limitations with these studies. In particular, participants were rarely
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presented with absolute estimates of effect or potential harms, nor with graphical representa-
tions of risk. Furthermore, the risk reductions were presented as variations in relative-risk
reduction from a fixed population average absolute risk, rather than variations in absolute risk
with a fixed relative-risk reduction. Relative risk formats have consistently been shown to pro-
duce more favourable evaluations of treatment options than absolute risk estimates [21] and
graphical representations to increase accuracy when making treatment decisions [22]. More-
over, in practice the relative-risk reduction for a given screening test is similar across risk
groups while the absolute risk varies. The findings from these existing studies, therefore, pro-
vide limited information to inform screening programmes.
To address these gaps in the literature, we used CRC screening as an exemplar to explore
how people make decisions about screening following presentation of information about dif-
ferent levels of absolute benefits and harms. We also aimed to determine the extent to which
preferences for screening vary with different levels of absolute risk of developing disease,
between different screening tests and between individuals. We hypothesised that there would
be considerable variation in how individuals use this information to make decisions regarding
CRC screening and the relative weight they attribute to the benefits, harms and burdens of
screening options. Further, we hypothesised that individuals would be more likely to opt for
screening at higher absolute risks of developing CRC and that those who have attended screen-
ing in the past or have a family history of CRC will be more likely to opt for screening at lower
absolute risks.
Methods
We conducted two linked studies. The first was a think-aloud study in which participants were
encouraged to verbalise their thought processes while completing a survey in which they were
presented with scenarios presenting different absolute benefits and harms of CRC screening
and asked to make decisions about screening. As well as providing in-depth data on how indi-
viduals use the information regarding benefits and harms to make decisions, that study also
enabled us to pilot the survey and refine it prior to the second study, an online randomised
experiment designed to quantify: 1)the extent to which intention to attend screening varies
with levels of absolute risk and between screening tests (the primary outcome); and 2) the
extent to which participant-level characteristics or the different screening tests were associated
with different patterns of responses across the three risk levels (the secondary outcome).
Part 1. Think-aloud interviews
Study design. Participants completed an online survey while “thinking-aloud” about their
internal thought processes. This think-aloud method originated within the field of psychology
[23] as a basis for investigating the mental processes underlying complex task performance. By
asking participants to verbalise their thoughts and spontaneously report what goes through
their minds while performing a task, the approach provides rich data on cognitive processes. It
has been widely used in many scientific disciplines, including how respondents make benefit-
risk trade-offs in discrete choice experiments [24]. It is, therefore, an appropriate method to
explore in-depth how people make decisions about screening.
Participants and recruitment. Through a market recruitment company (iPoint Market
Research, www.i-point.co.uk), we recruited 20 members of the public between 45–79 years of
age without a history of inflammatory bowel disease, hereditary non-polyposis colorectal can-
cer or familial adenomatous polyposis. Participants were purposively sampled by age, gender,
ethnicity, education background and prior screening history.
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Survey. We developed the survey used for the think-aloud study in collaboration with our
patient or public involvement (PPI) members. S1 File provides full details of all the questions
and measures. The survey began with a series of questions on key personal characteristics: age,
sex, ethnicity, education level, family history of CRC, numeracy (Schwartz scale [25]), percep-
tion of their own CRC risk (assessed on a 7-point Likert scale from likely to unlikely), cancer
worry (Lerman cancer worry scale [26]), and whether they had attended and/or been invited
for CRC screening. Validated instruments and questions were used for these questions where
possible.
Participants then reported what they knew about CRC screening before reviewing details
regarding CRC. To ensure that participants were able to understand what each test involves
and make an informed decision about whether to take up screening, this included a descrip-
tion of the three most common screening tests (colonoscopy, sigmoidoscopy and Faecal
Immunochemical Testing (FIT)) and their associated burdens/harms. Online information
related to the Bowel Cancer Screening Programme in England reviewed by our PPI members
informed the descriptions of the screening tests. A literature review informed the burdens and
harms (Web Appendix 5 in [10]). Burdens included preparation prior to each test, what is
involved during the test, how long having the test would take, any likely pain and any need to
rest afterwards. Harms for FIT included those resulting from colonoscopy if a FIT test came
back positive and for both sigmoidoscopy and colonoscopy included the risk of bleeding or
bowel perforation. S1 File provides full details. After reading that information, participants
provided a global rating of the burden, inconvenience or worry they associated with each
screening test on a 5-point Likert scale from 1 “No inconvenience, burden or worry” to 5
“Very great inconvenience, burden or worry”.
Participants then saw nine scenarios that presented the absolute benefits and harms associ-
ated with three different 15-year absolute risks of developing CRC (1%, 3% and 5%) for each
of the three screening tests (FIT, sigmoidoscopy and colonoscopy). The scenarios were
grouped by screening test with participants randomised to groups with one of the following
orders: 1) FIT, sigmoidoscopy, colonoscopy; 2) sigmoidoscopy, colonoscopy, FIT; or 3) colo-
noscopy, FIT, sigmoidoscopy. The order in which participants saw the three 15-year absolute
risks of developing CRC within each of these groups was randomly allocated with each partici-
pant being randomised to one of the following orders: 1) 1%, 5%, 3%; 2) 5%, 3%, 1%; or 3) 3%,
1%, 5%. The order in which participants saw the 15-year absolute risks of developing CRC was
the same for each individual for all of the three screening tests. The range 1–5% 15 year risk
was chosen because this covers the range of risk levels observed in the general population [27]
and we wanted to assess the potential impact of providing accurate risk information within
screening programmes.
Each scenario was presented in a graphical representation that included estimates of the
absolute risk of CRC incidence and mortality, the risk reduction achieved through screening,
and the risk of complications requiring a visit to the emergency department or hospitalisation.
In order to inform the design of the graphical representation for the subsequent online experi-
ment, we developed two graphical representations for the think-aloud study, a bubble format
and a bar format (Fig 1A), both informed by the literature addressing risk presentation [28–
31]. The bubble format was based on the information provided in the English Breast Cancer
Screening participant information leaflet that was developed during a four-step process involv-
ing experts and members of the public [32]. The bar format was included as an alternative to
enable us to explore whether a more visual comparison of the absolute benefits and harms
influenced how people understood and used the information. Prior to their use in the study,
both formats were piloted with our PPI representatives. They suggested a number of modifica-
tions, including clarifying that complications were those requiring a visit to the emergency
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department or hospitalisation and including details of the number of people with a normal
FIT test. These modifications were incorporated prior to data collection.
Participants were randomly assigned to one of the two formats, seeing all nine scenarios in
that format. In both formats, published data from a microsimulation study based on the
Microsimulation Screening Analysis-Colon model (MISCAN-Colon) [33] informed estimates
for the absolute benefits and harms (S1 Table).
Fig 1. Formats of risk presentation. Examples of the formats of presentation of absolute benefits and harms for faecal immunochemical testing (FIT) and 3%
baseline absolute risk used in a) The Think-aloud study and b) The online survey experiment.
https://doi.org/10.1371/journal.pone.0246991.g001
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After viewing each of the nine scenarios, participants were asked whether, on the basis of
the information, they would undergo screening “Based on this information, would you choose
to go for screening? Yes/No”.
To test understanding of the risk information, participants completed a test question after
the first scenario in which they were asked to select the correct number of CRC cases that
would be prevented in the scenario from four options. We additionally included an attention
check (“It is important that you pay attention in this study. Please tick ‘strongly disagree’”) early
in the questionnaire to identify inattentive participants [34].
Data collection. Using a discussion script as a guide (S2 File), an experienced qualitative
researcher (KM) conducted face-to-face interviews in participants’ homes between 25th April
and 8th May 2019. The interviewer initially confirmed participation and consent and then
asked a warm up question (“What did you to today before coming to the session?”) to build
rapport. Participants then completed the survey online on a tablet computer in front of the
researcher while she prompted them to verbalize their thoughts through encouraging ques-
tions such as “What are you thinking when you are looking at this image?” and “Can you
describe your reasons for choosing this answer?”. The interviews were audio-recorded using
encrypted audio-recorders and then transcribed verbatim.
Analysis. The transcripts were analysed using Thematic analysis [35]. One researcher
(KM) read the transcripts from early interviews to identify themes and developed an initial
coding frame. Aided by NVivo software [36], KM then coded the remainder of the transcripts
using that coding frame. This was followed by an interpretation stage during which she read
through the coded categories and identified the main concepts and ways in which different
parts of the data were related to each other. Three members of the research team (LL, LH and
MB) read a selection of transcripts and the four team members, and then the wider team, dis-
cussed the identified themes.
Part 2. Online survey
Study design. This was a randomised parallel group online experiment in which partici-
pants completed a shorter version of the survey used for the think-aloud study that included
only three scenarios covering three different 15-year absolute risks of CRC, all relating to the
same screening test and all with the bar presentation format alongside a pictograph (Fig 1B).
The team made the decision to use the bar presentation format alongside a pictograph and this
shortened version in which participants only saw three scenarios following analysis of the data
from the think-aloud study in part 1 and based on concern that in an online experiment partic-
ipants would lose interest if presented with all nine scenarios.
Stratified by whether they had been invited to screening in the past, participants were
randomised 1:1:1 at an individual level based on computer generated random numbers in
block sizes of three to one of FIT, sigmoidoscopy or colonoscopy scenarios. The order in
which participants viewed the scenarios was also randomly allocated using the same method
according to the absolute level of risk, with participants either viewing 1% followed by 5% then
3% (1–5–3), 3% followed by 1% then 5% (3–1–5) or 5% followed by 3% then 1% (5–3–1)
(Fig 2).
Participants and recruitment. We recruited 1000 participants who had not taken part in
the think-aloud study through an online participant recruitment platform developed for
research surveys and market research (www.prolific.ac) between 7th-8th June 2019. Participants
were eligible to take part if they were between 45–79 years of age; resident in the UK without a
past history of cancer; and had a Prolific approval rating�95%. The Prolific approval rating is
a measure of the proportion of studies completed by the participant that have subsequently
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been approved by the study team. Exclusion of participants with a low approval rating is con-
sidered good practice [37].
Data collection. As for the think-aloud study, the questions and scenarios were embedded
within an online survey. Except for the reduced number of scenarios, the questions were the
same as for the think-aloud study (S1 File). Participants who failed to answer the attention
check correctly were excluded prior to randomisation.
Analysis. Using the three responses from all participants, we first described the overall
proportion of participants expressing intention to attend screening at each risk level. To enable
us to explore the primary outcome, the extent to which intention differed with different levels
of absolute risk of developing CRC and between screening tests, we used multivariable logistic
regression with intention as the outcome and the risk level and screening test as explanatory
variables, accounting for clustering at participant level using cluster robust standard errors
and adjusting for whether participants had previously been invited for CRC screening (the
stratification variable used for randomisation) and the order in which participants were pre-
sented with the different risk levels. Hypothesizing that the order in which the risk levels were
presented might influence the response to a given risk level (for example, that intention to
attend at a risk level of 3% would be different when that was the first scenario presented versus
if it followed a risk level of 5%), we also tested for an interaction between the order and the risk
levels. Where significant, we present the results stratified by the order in which the risk levels
were presented.
To explore patterns in responses at an individual level, we then grouped participants into:
1) those who intended to take up screening at all three risk levels; 2) those who did not intend
to take up screening at any risk level; and 3) those whose responses varied with risk level. To
Fig 2. Participant flow diagram for online survey experiment.
https://doi.org/10.1371/journal.pone.0246991.g002
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identify whether patient-level characteristics or the different screening tests were associated
with different patterns of responses across the three risk levels (secondary outcome) we used
the Chi-squared test (unadjusted) and multinomial logistic regression (adjusted) to test for
associations between the likelihood of being in each of the three groups of response patterns
and the screening test (FIT, sigmoidoscopy or colonoscopy) and individual level characteristics
(age, sex, ethnicity, university level education, family history of CRC, prior history of screening
for CRC, numeracy, understanding of risk information and prior perceptions of screening).
In an exploratory analysis, we repeated all analyses stratified by whether participants cor-
rectly answered the test question. We report all regression analysis results as odds ratios (ORs)
with 95% confidence intervals or p values. All analyses were performed using Stata Version 14
[38] with statistical significance set at p<0.05.
Sample size. When designing the study, assuming an overall uptake of screening of 66%
[39] and intention to attend screening of 80%, 83% and 86% in groups with the three levels of
risk respectively, we estimated that 1000 participants would give us 90% power to detect a dif-
ference in intention across the different levels of risk.
Ethical approval and consent
The Cambridge Psychology Research Ethics Committee approved the study (PRE.2019.022).
All participants provided written online consent at the start of the study.
Results
Think-aloud study
The mean age of the 20 participants was 61.7 years (range 45–77 years). Eleven were female
and 17 were white British and had completed either secondary (n = 9) or university level
(n = 7) education. Ten had attended bowel cancer screening in the past. Fifteen correctly
answered the test question.
Despite verbalising the numbers presented in the scenarios, for many the information on
absolute benefits and harms did not appear to be a factor in their decision making. Twelve
intended to take up screening either again or for the first time in the future with all three
screening tests at any level of risk.
“I’ve already said that nothing would stop me going for a screening. So the statistics are really
irrelevant. Whether it’s 1 in 1,000 or 1 in a million, if there’s a chance of preventing it then I
would take no risk.” (Male, 60–64, prior CRC screening)
In most cases these participants appeared to be making decisions based on prior beliefs
around screening in general and did not appear to consider the specific burden or harms of
screening. Even when they mentioned the harms of the tests when explaining their decision,
they dismissed these almost immediately and described instead how they believed the benefits
outweighed any risks.
“The only thing that’s influencing me is my thoughts on screening and I still think the benefits
of being screened outweighs the complications.” (Female, 65–69, no prior CRC screening)
In these cases the benefits of screening were often described in the context of family mem-
bers’ experiences of the tests and personal concerns for developing cancer in the future. Again,
the absolute magnitude of these benefits did not appear to matter. Instead, a common view
was that as long as one person benefitted it was worth it because they could be that person.
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“It could be me. That death could be me. It could be my family member. So, even if it prevents
one death, I’d still do it.” (Male, 60–64, prior CRC screening)
For some of the participants (n = 7), the absolute benefits and harms and screening tests
did appear to influence their decisions.
“Well, if that [1%] was the percentage I’d think, “Well, is it really worth it?” The one doesn’t
increase your chance one way or the other, really, for having it, or not being screened.” (Male,
65–69, no prior CRC screening)
“Maybe I’d say a no for three, but if I was a five per cent, I might think about it.” (Female,
45–49, no prior CRC screening)
In many of these cases, decisions were not based on the risk level alone. Instead participants
were influenced by their previous experiences of the tests and the test characteristics. For
example, one participant felt that they would only accept screening with a colonoscopy at 5%
risk and would decline screening with FIT or sigmoidoscopy at that level because of a fear of
false-positives. Another appeared to substitute their own beliefs for the evidence provided, not
accepting screening with FIT below 5% risk because they felt it was not effective at lower risk
levels. One participant did not wish to attend screening for any of the tests at any risk level for
fear of complications from sigmoidoscopy and colonoscopy and a previous false positive from
a FIT test.
There were no clear patterns in the data with participant level characteristics or between the
two graphical representations. Some participants, however, found it difficult to follow the bub-
ble format. In particular, they did not appear to appreciate that some of the people who had an
abnormal result would not develop cancer.
Online experiment
At the time of recruitment, 3,555 participants met the eligibility criteria for the study. Of these,
1105 started the questionnaire and 1000 were randomised. 22 participants did not complete
responses for all three scenarios. 978 participants are therefore included in the analysis (Fig 2).
The characteristics of the 978 participants were balanced across each group, with no substan-
tial difference from the 22 who did not complete all three scenarios (S2 Table). Most were aged
between 45–65 years, female, of white ethnicity and without a family history of CRC. Half had
university level education. 61% (600/977) thought the benefits of CRC screening outweighed
potential harms for everyone. 51% (502/978) selected the correct response to the test question.
In univariable analysis, participants with high numeracy were more likely to select the correct
response than those with low numeracy (OR 1.36 (95% CI 1.00–1.85). There was no associa-
tion with age group, sex, ethnicity or university level education and the association with
numeracy failed to reach statistical significance in multivariable analysis including age, sex,
ethnicity and university level (AOR 1.39 (95% CI 0.98–1.89)).
Response to scenarios. The number of participants expressing intention to take up
screening in each of the nine study groups for all three scenarios is shown in S3 Table. Includ-
ing the three responses from all participants across all three screening tests, 60% (95% CI 57.2–
63.4%) expressed intention to attend screening at 1% 15-year risk, 70% (95% CI 68.4–74.2%)
at 3% and 77% (95% CI 74.4–79.8%) at 5% (Fig 3). In multivariable analysis there were no sig-
nificant differences in intention between the three screening tests (OR 0.93 ((95% CI 0.70–
1.25) for sigmoidoscopy compared with FIT and OR 0.83 (95% CI 0.62–1.11) for colonoscopy
compared with FIT) but both the baseline risk level and the order in which participants were
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presented with the different risk levels were significantly associated with intention to attend
screening. A significant interaction existed between the risk level and order in which the par-
ticipants were presented with the different risk levels. Stratifying the results by the order in
which the risk levels were presented showed that in all three orders participants were more
likely to take up screening as the risk level increased (Tables 1 and S4). The relative difference
in intention between the three risk levels varied with the order, with the strongest association
between risk and intention seen in the groups who saw 5% followed by 3% followed by 1%.
Repeating this analysis stratified by response to the test question after the first scenario
showed that the association between risk level and intention to take up screening was slightly
stronger in those selecting the correct response (S5 Table).
Grouping the participants who saw scenarios relating to FIT, sigmoidoscopy and colonos-
copy, Fig 4 shows the patterns of responses across the three risk levels for each individual par-
ticipant. 535 (54.7% (95% CI 51.5–57.9%)) individuals said yes to all three scenarios and 178
(18.2% (95% CI 15.8–20.8%)) said no to all three scenarios. 265 (27.1% (95% CI 24.3–30.0%))
Fig 3. Percentage (± 95% confidence interval) of participants expressing intention to attend screening for each baseline risk
level and screening test.
https://doi.org/10.1371/journal.pone.0246991.g003
Table 1. Odds ratios (ORs) of intention to attend screening at each baseline 15 year percentage risk of CRC and
for each order in which participants were presented with the three scenarios.
15-year risk (%) Order in which participants were presented with the risk levels
1—5—3 3—1—5 5—3—1
1 1 (ref) 1 (ref) 1 (ref)
3 1.17 (0.95 to 1.44) 1.75 (1.45 to 2.10) 1.83 (1.49 to 2.25)
5 1.56 (1.22 to 2.00) 2.31 (1.83 to 2.92) 2.92 (2.28 to 3.74)
ORs are adjusted for screening test, previous invitation to screening and stratified by baseline percentage risk and
order.
https://doi.org/10.1371/journal.pone.0246991.t001
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individuals responded differently across the three scenarios, suggesting that the absolute bene-
fits and harms influenced their decision. Among those, 120 said no at 1% but yes at 3% and 5%
(indicating a threshold between 1–3%) and 77 said no to 1% and 3% but yes to 5% (indicating
a threshold between 3–5%). 68 provided inconsistent responses saying yes at either 1% or 3%
and no at 3% or 5%.
Table 2 shows the characteristics of the participants in each of those response groups
(always yes, always no and scenario dependent). In unadjusted analysis, the distribution of par-
ticipants within those three groups varied with screening test, ethnicity, family history of CRC,
prior history of screening, numeracy and prior beliefs around screening. These observed dif-
ferences with ethnicity, family history of CRC, prior history of screening and prior beliefs
about screening persisted in multivariable analysis (Tables 2 and S6). Participants with a family
history of CRC and those who had attended screening previously were more likely to say yes at
all risk levels and those of non-White ethnicity were more likely to respond differently across
the three risk levels. Additionally, age was significant in multivariable analysis, with older indi-
viduals more likely to say no to all scenarios. There was no association between response
group and whether or not participants answered the test question correctly.
Discussion
Consistent with our hypothesis, these two linked studies have shown that there is considerable
variation in how individuals use information regarding absolute benefits and harms of screen-
ing to make CRC screening decisions. Overall individuals in the online experiment were more
likely to intend to take up screening at higher absolute baseline 15-year risks of developing
CRC. However, many (up to half of participants in both studies) did not fully understand the
Fig 4. Participants expressing an intention to attend screening at each risk level across the three scenarios for FIT, sigmoidoscopy and colonoscopy
combined.
https://doi.org/10.1371/journal.pone.0246991.g004
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information and, within the range of absolute benefits and potential harms presented, the
majority did not vary their decisions about whether to take up screening on the basis of the
range of the number of cases or deaths from CRC that screening could prevent or the potential
risk of complications from screening tests. Data from the think-aloud study suggests that for
these individuals, their prior perceptions of screening and, for those opting for screening,
the view that screening is worthwhile as long as one person might benefit, exert greater
influence.
Table 2. Response patterns to the scenarios stratified by study variables.
Variable Always no (N = 178) n
(unadjusted %)
Scenario dependent (N = 265) n
(unadjusted %)






Screening test 0.044 0.085
FIT 48 (14.7) 94 (28.8) 185 (56.6)
Sigmoidoscopy 67 (20.6) 72 (22.2) 186 (57.2)
Colonoscopy 63 (19.3) 99 (30.4) 164 (50.3)
Age (years) 0.294 0.002
45–54 95 (16.6) 166 (29.0) 311 (54.4)
55–64 61 (19.4) 79 (25.2) 174 (55.4)
>65 22 (23.9) 20 (21.7) 50 (54.4)
Sex 0.085 0.063
Female 125 (19.4) 183 (28.4) 336 (52.2)
Male 53 (15.9) 82 (24.6) 199 (59.6)
Ethnicity 0.028 0.046
White 172 (18.4) 246 (26.3) 517 (55.3)




Yes 89 (17.6) 146 (28.8) 272 (53.7)
No 89 (18.9) 119 (25.3) 263 (55.8)
Family history 0.001 0.013
No 163 (18.7) 247 (28.3) 462 (53.0)




No 159 (20.9) 217 (28.5) 385 (50.6)
Yes 19 (8.8) 48 (22.1) 150 (69.1)
Numeracy 0.034 0.051
Low 45 (21.7) 42 (20.3) 120 (58.0)




Incorrect 90 (18.9) 124 (26.1) 262 (55.0)




Yes for all 44 (7.3) 160 (26.7) 396 (66.0)
No for all 4 (20.0) 4 (20.0) 12 (60.0)
It depends 130 (36.4) 101 (28.3) 126 (35.3)
� Adjusted for all factors included in the table in addition to the order in which the scenarios were presented.
https://doi.org/10.1371/journal.pone.0246991.t002
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For a significant minority of people (27% in the online experiment), the absolute benefits
and harms from screening do appear to be influential. Consistent with our hypotheses, these
individuals are more likely to not have a family history of CRC and not have attended CRC
screening in the past. Additionally, they are more likely to be younger and not believe that
CRC screening is beneficial for everyone.
Notably, despite following best-practice [28, 31] and piloting the presentation formats with
PPI members, many of the participants were unable to correctly select the number of cases of
CRC prevented in the first scenario. Moreover, whether or not participants were influenced by
the absolute benefits and harms was independent of the responses to that test question. The
association between risk level and intention to take up screening was only slightly stronger in
those who selected the correct response. That five of the 20 participants in the think-aloud
study failed to provide a correct answer despite actively talking through the data suggests that
these incorrect responses may reflect a lack of understanding rather than a lack of attention.
Even among the group for whom the absolute benefits and harms appear to be influential, how
the quantitative information influenced decision-making remains uncertain.
Although this is the first study to our knowledge to directly explore the impact of different
absolute benefits and harms from screening among individuals, these findings are consistent
with a previous online scenario-based study in which only 23% of 1,675 female participants
varied their decisions on risk reduction mastectomy according to baseline risk of breast cancer
mortality and the expected risk reduction due to mastectomy [40]. Surveys and focus groups
in the context of breast cancer screening [41, 42], reviews of personalised risk communication
[43, 44], and the wider decision-making literature [45–47] have also documented that deci-
sions are often influenced by emotions and attitudes not by quantitative risk-based
information. . . The difficulty lay individuals have understanding quantitative risk-based infor-
mation is also well known [14], with the high proportion of participants who did not get the
test question correct in this study is consistent with assessment of knowledge in a randomised
trial of a web-based decision aid for breast cancer screening in which less than 30% of women
correctly identified the number of women who will avoid dying from breast cancer because of
screening or how many women not undergoing screening will die from breast cancer [48]. An
important addition to the literature that this study provides is characterisation of those indi-
viduals for whom risk information does and does not appear to influence decisions concerning
screening, enabling targeting of future interventions.
A key strength of this study is the mixed-methods design, incorporating both a qualitative
think-aloud study to explore individuals’ thoughts and reasoning in depth and pilot the survey
and a quantitative online experiment to describe patterns in responses and associations with
participant level characteristics.
There are, however, a number of limitations. First, we only assessed intention within the
range from 1% to 5% 15-year risk. While this range covers the average 15-year risk of CRC in
UK adults between the ages of 50 and 74 years [27] and the think-aloud study findings suggest
that the magnitude of the risk was not important to individuals whose responses did not vary
with risk, we do not know if those individuals who appeared to be insensitive to risk may have
thresholds outside this range. Secondly, although our recruitment strategy allowed for purpo-
sive sampling for the think-aloud study and a large sample size for the survey, the demograph-
ics of members of recruitment agencies are not necessarily representative of the UK
population [49]. Additionally, over 90% of our population were of white ethnicity and few
were over 60 years old. The large sample size also increases the chance of detection of small
but unimportant effects. However, the magnitude of the differences we observed are substan-
tial and comparable with the effect sizes seen in studies designed to increase uptake of screen-
ing [50, 51].
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Thirdly, we conducted this study in the UK where there is an existing CRC screening pro-
gramme. Most people (70%) were aware of this national programme and exposure to recom-
mendations for screening may have influenced their views, particularly as there is less
controversy surrounding CRC screening programmes than other screening programmes such
as breast cancer. Fourthly, we considered only one timeframe of 15 years. Studies in cardiovas-
cular disease have shown that shorter timeframes may result in more accurate risk perceptions
and increased intention to change behaviour, especially for older people [52]. It is therefore
possible that different timeframes would have different influences on individuals’ decision
making, especially when considering different age groups. Finally, the study required partici-
pants to imagine that each scenario related to them and we measured intention rather than
behaviour. Such hypothetical intention rates may not reflect subsequent uptake [53].
Conclusion
The majority of people in these two studies were uninfluenced by the range of absolute benefits
and harms associated with CRC screening presented. This suggests that providing additional
information on absolute benefits and harms, either in the context of initiatives to improve
informed choice or in risk-stratified approaches, may have little impact on the decisions the
majority of people make about screening. These findings also raise important future research
questions around the meaning and measurement of informed choice in the context of screen-
ing. Traditional measures of informed choice consider individuals to have made an informed
choice when their knowledge, attitudes and behaviour are consistent [54]. Our findings sug-
gest that individuals may have adequate knowledge and this may be consistent with their atti-
tudes, but that they may not be using that knowledge to make their decision.
For an appreciable minority, however, the magnitude of benefit appeared to be important.
These individuals are more likely to be younger, to not have a family history of CRC and to
not have previously attended screening. Providing information on absolute benefits and
harms when people are first invited to screening may therefore have a greater impact on deci-
sion making than providing it at subsequent invitations. The high proportion of participants,
including those for whom the magnitude of benefit was important, who did not understand
the information presented in this study, also highlights the need for further research into how
best to present the information and the potential challenges of using such information to
incorporate risk stratification into screening programmes.
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